Maintenance of cancer stemness drives lung cancer recurrence, metastasis, and refractoriness. Limited drug efficacy against existing stemness mechanisms suggests the existence of undiscovered complex regulatory networks. Previously, we found that RAD51AP1 is positively associated with lung cancer stemness; here, we showed that it promotes stemness maintenance in vitro and in vivo. Mechanistically, using cleavage under targets and tagmentation (CUT&Tag), dual-luciferase reporter assay (DLRA), DNA pull-down-WB, and chromatin immunoprecipitation (ChIP)-qPCR, we confirmed that RAD51AP1 transcriptionally upregulates MYC by binding to its promoter region, thereby enhancing stemness. Using a DNA pull-down assay combined with liquid chromatography-mass spectrometry (LC-MS), DLRA, and ChIP-qPCR, we verified that Sam68 binds the RAD51AP1 promoter to enhance its transcription. More importantly, MYC, conversely, targets the Sam68 promoter and upregulates its transcription. Thus, we identified a lung cancer stemness regulatory model: the RAD51AP1-MYC-Sam68-RAD51AP1 positive transcriptional feedback loop. Targeting this cascade has the potential to reverse cancer stemness and advance clinical therapies.
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com